Study Demonstrates Performance of SMARTag Platform
New toxicology study demonstrates decreased mortality and better tolerability of ADC generated with Smartag platform versus conventional technology.
Redwood Bioscience and Catalent Pharma Solutions have announced the results of an in vivo toxicology study, demonstrating that an antibody drug conjugate (ADC) generated using the proprietary SMARTag platform has a better toxicity profile than a conventional ADC.
The study, conducted in a rat model by Redwood Bioscience compared the effects of a single dose of 6, 20 or 60 mg/kg of a SMARTag ADC conjugated to a cytotoxic payload using the proprietary HIPS chemistry, to an ADC generated with traditional conjugation methods.
Results showed that the SMARTag ADC was well tolerated and provided statistically significant survival benefits versus the conventional ADC, particularly at high doses where the conventional ADC resulted in mortality. Elevations in liver enzymes and decreases in platelet counts and reticulocytes were also observed with the conventional ADC at 20 and 60mg/kg treatments, whereas these effects were only seen with the highest dose of the SMARTag ADC. In addition the toxicokinetic analysis showed that the SMARTag ADC had greater exposure and longer circulating half-life than the conventional ADC comparator.
Toxicology study results have been published and are available in the Journal of Bioconjugate Chemistry.
Source: Catalent
